China approves Pfizer's GLP-1 drug for weight management, intensifying market competition
Source: SeekingAlpha
2026-03-06 02:27:55 ET
More on Pfizer
- Pfizer: Obesity Hype And Vaccine Policy Shocks
- Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
- Pfizer's Quiet Cash Comeback
- Pfizer-backed Priovant wins FDA priority review for lead asset
- FDA reportedly eyeing staff bonuses to accelerate drug reviews
Read the full article on Seeking Alpha
For further details see:
China approves Pfizer’s GLP-1 drug for weight management, intensifying market competition
Novo Nordisk A/S
NASDAQ: NVO
NVO Trading
0.57% G/L:
$38.835 Last:
8,264,234 Volume:
$38.73 Open:
NVO Latest News
March 09, 2026 12:44:07 pm
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
NVO Stock Data
$220,548,675,000
4,194,421,000
N/A
749
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
